Get the Stockscreener App
3.18
1.24%
-0.04
After Hours:
3.2888
0.1088
+3.42%
Tempest Therapeutics Inc stock is currently priced at $3.18, with a 24-hour trading volume of 316.43K.
It has seen a -1.24% decreased in the last 24 hours and a -2.75% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $3.27 pivot point. If it approaches the $3.17 support level, significant changes may occur.
Previous Close:
$3.22
Open:
$3.21
24h Volume:
316.43K
Market Cap:
$70.65M
Revenue:
-
Net Income/Loss:
$-31.11M
P/E Ratio:
-1.3361
EPS:
-2.38
Net Cash Flow:
$-28.18M
1W Performance:
-2.15%
1M Performance:
-2.75%
6M Performance:
-8.09%
1Y Performance:
+55.88%
1D Range:
$3.12
$3.26
52W Range:
$0.17
$9.77
Tempest Therapeutics Inc Stock (TPST) Company Profile
Name
Tempest Therapeutics Inc
Sector
Industry
Phone
415 798 8589
Address
7000 Shoreline Court, Suite 275, South San Francisco
Tempest Therapeutics Inc Stock (TPST) Latest News
Short Interest in Tempest Therapeutics, Inc. (NASDAQ:TPST) Increases By 39.8% - MarketBeat
MarketBeat
Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
MarketBeat
Tempest Therapeutics' (TPST) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
MarketBeat
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
GlobeNewswire
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire Inc.
Tempest Reports First Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
GlobeNewswire
Tempest Therapeutics Inc Stock (TPST) Financials Data
Tempest Therapeutics Inc (TPST) Net Income 2024
TPST net income (TTM) was -$31.11 million for the quarter ending September 30, 2023, a +9.54% increase year-over-year.
Tempest Therapeutics Inc (TPST) Cash Flow 2024
TPST recorded a free cash flow (TTM) of -$28.18 million for the quarter ending September 30, 2023, a +14.11% increase year-over-year.
Tempest Therapeutics Inc (TPST) Earnings per Share 2024
TPST earnings per share (TTM) was -$2.20 for the quarter ending September 30, 2023, a +41.42% growth year-over-year.
About Tempest Therapeutics Inc
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
0.77%
1.20%
Cap:
|
Volume (24h):